Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
About Us - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Events - Targeted Oncology
Targeted Oncology™ offers a variety of events designed to generate educational discourse and networking among oncologists practicing in a community setting. Events are centered around a particular disease state and feature prominent and respected key opinion leaders. Case-Based Roundtables are collaborative, small-group meetings designed around case-based clinical profiles and peer-dialogue ...
Targeted Therapies in Oncology - Targeted Oncology
Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with its meeting coverage, columns, FDA news, and more. Click Here to Subscribe
Tislelizumab Scores FDA Approval in Advanced Gastric and GEJ …
4 天之前 · The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma. Tiselizumab (Tevimbra), an anti–PD-1 monoclonal antibody, plus chemotherapy for the first-line treatment of ...
Latest Conference Articles - Targeted Oncology
2024年11月15日 · A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
ADCs Change the Game for Cancer Treatment - Targeted Oncology
2024年5月29日 · Loncastuximab Tesirine. The CD19-directed loncastuximab tesirine-lpyl (Zynlonta) gained an FDA orphan drug designation in 2017 7 and was granted accelerated approval in April 2021 for patients with large B-cell lymphoma. The approval was supported by the LOTIS-2 study (NCT03589469), which enrolled 145 patients who were relapsed/refractory to at least 2 prior treatments.
Podcasts - Targeted Oncology
Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.
Treatment Resources - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Targeted Publications
Peers & Perspectives® in Oncology delivers exclusive coverage of virtual and in-person live events held by Targeted Oncology and Healthcare Research & Analytics®, thought leader collaborations, and community input on the growing targeted therapy space to encourage peer-informed decision-making in various disease states.. Featuring candid conversations among community and academic oncologists ...